Concepedia

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Chloe Orkin, Edwin DeJesus, Paul E. Sax, José Ramón Arribas, Samir K. Gupta, Claudia Martorell, Jeffrey L. Stephens, Hans‐Jürgen Stellbrink, David A. Wohl, Franco Maggiolo,

The Lancet HIV · 2020 · 128 citations · 19 references

DOIFull text

Open access

Abstract

Gilead Sciences.

References

19

Obesity and the Environment: Where Do We Go from Here?

James O. Hill, Holly R. Wyatt, George Reed et al. · Science · 2003 · 2.2K citations

, , +20

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Paul E. Sax, Kristine M. Erlandson, Jordan E. Lake et al. · Clinical Infectious Diseases · 2019 · 723 citations · Full text

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Michael S. Saag, Constance A. Benson, Rajesh T. Gandhi et al. · JAMA · 2018 · 551 citations · Full text

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Paul E. Sax, Anton Pozniak, Marisa Montes et al. · The Lancet · 2017 · 385 citations

, , +11

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Joel E. Gallant, Adriano Lazzarin, Anthony Mills et al. · The Lancet · 2017 · 362 citations

, , +9